Research Grade Dulaglutide

Catalog No.

DHE40129

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

Fusion-[GCG (glucagon) 98-127 (glucagon-like peptide 1, GLP1) 7-36]2-IgG4-Fc (Fragment constant)

Clonality

Monoclonal

Target

GLP-1 receptor, Glucagon-like peptide 1 receptor, GLP1R, GLP-1-R, GLP-1R

Concentration

0.8 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P43220

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

CAS: 923950-08-7

Clone ID

Dulaglutide

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, PMID: 31189511

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial, PMID: 29397376

Dulaglutide for the treatment of type 2 diabetes, PMID: 28274140

Dulaglutide: A Review in Type 2 Diabetes, PMID: 32002850

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial, PMID: 32333876

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial, PMID: 32562683

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial, PMID: 31189509

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11), PMID: 33397768

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial, PMID: 29910024

Dulaglutide, PMID: 31643312

Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial), PMID: 32865597

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial, PMID: 29483060

Dulaglutide for type 2 diabetes, PMID: 30410215

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial, PMID: 25018121

Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review, PMID: 32524494

Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial, PMID: 30129089

Dulaglutide, PMID: 30000038

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial, PMID: 31924562

Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin, PMID: 31050143

Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies, PMID: 32109448

Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States, PMID: 30520248

Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials, PMID: 29377522

Dulaglutide efficacy, PMID: 31048937

Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data, PMID: 32945083

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER), PMID: 31646727

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study, PMID: 25912221

Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review, PMID: 26742577

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3), PMID: 24842985

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2), PMID: 26089386

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1), PMID: 24879836

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program, PMID: 27102969

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study, PMID: 26009229

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5), PMID: 24742660

Dulaglutide: A Review in Type 2 Diabetes, PMID: 26423061

Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study, PMID: 33367981

Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better, PMID: 33446799

Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin, PMID: 33197271

Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes, PMID: 31185450

Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results, PMID: 33256915

Dulaglutide: first global approval, PMID: 25367716

Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes, PMID: 25657615

Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?, PMID: 32564337

Dulaglutide (Addendum to Commission A15-07) [Internet], PMID: 29144655

Dulaglutide for the treatment of type 2 diabetes, PMID: 24918645

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials, PMID: 31422062

Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes, PMID: 25565404

Dulaglutide slows kidney disease in type 2 diabetes, PMID: 32087784

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide, PMID: 26316788

Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study, PMID: 32308446

Mode of administration of dulaglutide: implications for treatment adherence, PMID: 27330280

Document Download

Research Grade Dulaglutide.pdf